The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer

Yoon, Kyoungro; Yoon, Hye-Kyoung; Park, Sohee; Jang, Hyun‐June; Zo, Jae Ill; Lee, Hyun-Sung; Lee, Jin Soo

doi:10.1016/j.jtcvs.2012.06.030

Cited by 56 publications

(55 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiR-27a expression is up-regulated in breast cancer (41) but down-regulated in colorectal cancer and oral squamous carcinoma and expressed at low levels in both the serum and plasma of NSCLC patients (26,42,43). It is also reported that an reference single nucleotide polymorphism (rs)895819 SNP was found in precursor miRNA (premiR)-27a in NSCLC patients (44). As shown in Figs.…”

Section: Discussionmentioning

confidence: 85%

Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2

Acunzo

Romano

Palmieri

et al. 2013

Proc. Natl. Acad. Sci. U.S.A.

107

View full text Add to dashboard Cite

In the past decade, we have observed exciting advances in lung cancer therapy, including the development of targeted therapies. However, additional strategies for early detection and tumor-based therapy are still essential in improving patient outcomes. EGF receptor (EGFR) and MET (the receptor tyrosine kinase for hepatocyte growth factors) are cell-surface tyrosine kinase receptors that have been implicated in diverse cellular processes and as regulators of several microRNAs (miRNAs), thus contributing to tumor progression. Here, we demonstrate a biological link between EGFR, MET, and the miRNA cluster 23a∼27a∼24-2. We show that miR27a regulates MET, EGFR, and Sprouty2 in lung cancer. In addition, we identify both direct and indirect mechanisms by which miR-27a can regulate both MET and EGFR. Thus, we propose a mechanism for MET and EGFR axis regulation that may lead to the development of therapeutics in lung cancer.cell signaling | epigenetics L ung cancer remains the number one cause of cancer-related deaths among men and women. However, in the past several years, we have witnessed some major advances in therapeutics that have improved outcomes in selected subgroups of patients. Tyrosine kinase receptors continue to be investigated as therapeutic targets in lung cancer. The receptor tyrosine kinase for hepatocyte growth factors, MET, is a membrane receptor for the hepatocyte growth factor (HGF) (1); MET tyrosine kinase is known to promote survival of many cell types following exposure to various apoptotic inducers, including serum starvation, death receptor activation, or genotoxic treatment (2). MET protein expression and phosphorylation have been associated with primary resistance to EGF receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy in non-small cell lung cancer (NSCLC) patients (3). EGFR is a membrane receptor overexpressed in most NSCLC tumors, and its activation and signaling contribute to both the growth and maintenance of epithelial tissues (4-6). MET and EGFR are normally expressed by cells of epithelial origin and, upon ligand stimulation, induce cancer cell invasion, thus increasing metastatic potential. This effect on invasion occurs primarily through increased phosphorylation of both ERK1/2 and the ETS domain containing protein (ELK)1 transcriptional factor (7-9). MET and EGFR protein levels are positively regulated by Sprouty2 protein expression (10-12). Sprouty2 is ubiquitously expressed at different levels in human tissues (13). Sprouty2 expression has been shown to increase MET protein levels in colon adenocarcinoma and also to increase EGFR levels by attenuating EGFR degradation by ubiquitination (10,12,14). MicroRNAs (miRNAs) are small noncoding RNAs of 19-25 nt that can inhibit mRNA translation and/or negatively regulate mRNA stability (15). MiRNA dysregulation is one of the most important factors contributing to cancer development (16) and has been implicated in cancer drug resistance (17). Several miRNAs are indeed involved in cancer initiation and progression such as miR-15 and...

show abstract

Section: Discussionmentioning

confidence: 85%

Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2

Acunzo

Romano

Palmieri

et al. 2013

Proc. Natl. Acad. Sci. U.S.A.

107

View full text Add to dashboard Cite

show abstract

“…Recently, Yoon et al reported that rs895819 of miR-27a was not associated with prognosis in patients with completely resected NSCLC in Korean population (Yoon et al, 2012). A study conducted by Xu et al suggested that miR-27a rs895819 polymorphism might influence NSCLC patients' clinical outcome (Xu et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

“…Rs895819, a SNP locus located in the terminal loop of pre-miR-27a, was reported to be significantly associated with the risk of gastric and cervical cancers (Sun et al, 2010;Xiong et al, 2014). However, there is no study reported the association between the locus and the risk of NSCLC, and prognostic results between them remain elusive (Xu et al, 2013;Yoon et al, 2012). Therefore, in order to address the role of rs895819 in the risk and prognosis of NSCLC, we genotyped the locus in 560 NSCLC patients and 568 healthy check-up individuals and followed-up the cases to examined the possible association between them.…”

Section: Rs895819 Within Mir-27a Might Be Involved In Development Of mentioning

confidence: 99%

Rs895819 within miR-27a Might be Involved in Development of Non Small Cell Lung Cancer in the Chinese Han Population

Yan²,

Yang³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

MicroRNA-27a (miR-27a) is deemed to be an oncogene that plays an important role in development of various cancers, and single nucleotide polymorphism (SNP) of miR-27a can influence the maturation or aberrant expression of hsa-miR27a, resulting in increased risk of cancer and poor prognosis for non-small cell lung cancer (NSCLC). This study aimed to assess the effects of rs895819 within miR-27a on susceptibility and prognosis of NSCLC patients in 560 clinical confirmed cases and 568 healthy check-up individuals. Adjusted odds/hazard ratios (ORs/HRs) and 95% confidential intervals (CIs) were calculated to evaluate the association between rs895819 and the risk and prognosis of NSCLC. The results showed that allele A and genotype GG of rs895819 were significantly associated with an increased risk of NSCLC (38.9% vs 30.8%, adjusted OR=1.26, 95%CI=1.23-1.29 for allele G vs A; 18.1% vs 11.7%, adjusted OR=1.67, 95%CI=1.59-1.75 for genotype GG vs AA). Moreover, positive associations were also observed in dominant and recessive models (53.7% vs 49.9%, adjusted OR=1.17, 95%CI=1.13-1.20 for GG/AG vs AA; 18.1% vs 11.7%, adjusted=1.65, 95%CI=1.58-1.73). However, no significant association was found between rs895819 and the prognosis of NSCLC in genotype, dominant and recessive models. These results suggested that miR-27a might be involved in NSCLC carcinogenesis, but not in progression of NSCLC. The allele G, genotype GG and allele G carrier (GG/AG vs AA) of rs895819 might be genetic susceptible factors for NSCLC. Further multi-central, large sample size and well-designed prospective studies as well as functional studies are warranted to verify our findings.

show abstract

“…Out of the Twenty-five, seven articles were pooled analysis, commentary and review papers (Wang et al, 2012;Yang and Burwinkel, 2012;Ma et al, 2013;Wang et al, 2013;Xu et al, 2013b;Zhong et al, 2013;Chen et al, 2014), and four reports were cancer biology experimental studies (Hirota et al, 2012;Jahid et al, 2012;Zanetti et al, 2012;Yuan et al, 2013). Three studies were excluded given that they did not include controls (Yoon et al, 2012;Xu et al, 2013a), or reported non-cancer disease (Song et al, 2013). We also included five eligible articles by manual searching (Li, 2011;Zhang, 2011;Zhang, 2012;Xu et al, 2013b;Kupcinskas et al, 2014), in which the study by Li et al included two independent case-control studies (Li, 2011) and the pooled analysis by Xu et al included one unpublished paper with efficient case-control study data (Xu et al, 2013b).…”

Section: Characteristics Of Studiesmentioning

confidence: 99%

Association of a Pre-miR-27a Polymorphism with Cancer Risk: an Updated Meta-analysis

Bai

Weng²,

Su³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer

Abstract: Our findings suggest that polymorphisms in the rs2910164 of miR-146a and the rs11614913 of miR-196a2 are associated with prognosis in patients with completely resected NSCLC.

Cited by 56 publications

References 25 publications

Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2

Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2

Rs895819 within miR-27a Might be Involved in Development of Non Small Cell Lung Cancer in the Chinese Han Population

Association of a Pre-miR-27a Polymorphism with Cancer Risk: an Updated Meta-analysis

Contact Info

Product

Resources

About